Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker RCUS · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other So… NCT05536141 · Clear Cell Renal Cell Carcinoma, Solid Tumors Casdatifan, Cabozantinib | RCUS Arcus Biosciences, Inc. | Phase 1 | Recruiting | 512 | Mar 2029 | Registry ↗ |
| Nov 2, 2026 | Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clea… NCT07011719 · Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear… Casdatifan, Cabozantinib | RCUS Arcus Biosciences, Inc. | Phase 3 | Recruiting | 720 | Apr 2028 | Registry ↗ |
| Nov 2, 2026 | Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic… NCT06608927 · Metastatic Pancreatic Ductal Adenocarcinoma Quemliclustat, Placebo | RCUS Arcus Biosciences, Inc. | Phase 3 | Active, not recruiting | 610 | Nov 30, 2030 | Registry ↗ |
| Nov 2, 2026 | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers NCT05891171 · Advanced Cancer, Advanced Malignancies AB598, Zimberelimab | RCUS Arcus Biosciences, Inc. | Phase 1 | Active, not recruiting | 40 | Sep 2027 | Registry ↗ |
| Oct 26, 2026 | A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Partic… NCT05329766 · Gastrointestinal Tract Malignancies Domvanalimab, Quemliclustat | RCUS Arcus Biosciences, Inc. | Phase 2 | Completed | 332 | Sep 7, 2026 | Registry ↗ |
| Oct 19, 2026 | Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer NCT04736173 · Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung… Domvanalimab, Zimberelimab | RCUS Arcus Biosciences, Inc. | Phase 2 | Completed | 169 | Sep 17, 2026 | Registry ↗ |
| Oct 9, 2026 | A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies NCT06120075 · Advanced Cancer AB801, Docetaxel | RCUS Arcus Biosciences, Inc. | Phase 1 | Completed | 29 | Apr 29, 2026 | Registry ↗ |
| Sep 9, 2026 | A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Mali… NCT04104672 · Advanced Pancreatic Cancer AB680, Zimberelimab | RCUS Arcus Biosciences, Inc. | Phase 1 | Completed | 196 | Jul 21, 2026 | Registry ↗ |
| Sep 4, 2026 | Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus… NCT07751250 · Healthy Participants, Hepatic Impairment Casdatifan | RCUS Arcus Biosciences, Inc. | Phase 1 | Recruiting | 16 | May 2027 | Registry ↗ |
| Sep 3, 2026 | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy,… NCT05568095 · Advanced Upper Gastrointestinal Tract Adenocarcinoma Domvanalimab, Zimberelimab | RCUS Arcus Biosciences, Inc. | Phase 3 | Completed | 1,040 | Aug 28, 2026 | Registry ↗ |
| Aug 25, 2026 | A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants NCT07662057 · Healthy Volunteers AB102, Placebo | RCUS Arcus Biosciences, Inc. | Phase 1 | Recruiting | 130 | Dec 2026 | Registry ↗ |
| Aug 13, 2026 | A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan… NCT07641881 · Healthy Participants Casdatifan | RCUS Arcus Biosciences, Inc. | Phase 1 | Completed | 24 | Jul 3, 2026 | Registry ↗ |
| Jun 15, 2026 | Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive N… NCT04262856 · Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung… Domvanalimab, Etrumadenant | RCUS Arcus Biosciences, Inc. | Phase 2 | Completed | 151 | Jul 9, 2025 | Registry ↗ |
| May 1, 2026 | Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-2… NCT07364214 · Healthy Participants Quemliclustat | RCUS Arcus Biosciences, Inc. | Phase 1 | Completed | 8 | Apr 6, 2026 | Registry ↗ |
| Nov 13, 2025 | Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29) NCT06919991 · Healthy Participants Casdatifan, Itraconazole | RCUS Arcus Biosciences, Inc. | Phase 1 | Completed | 14 | Oct 18, 2025 | Registry ↗ |
| Oct 20, 2025 | An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Comb… NCT04660812 · Metastatic Colorectal Cancer AB680, Etrumadenant | RCUS Arcus Biosciences, Inc. | Phase 1/2 | Completed | 227 | Sep 5, 2025 | Registry ↗ |
| Aug 28, 2025 | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies NCT04772989 · Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC) AB308, Zimberelimab | RCUS Arcus Biosciences, Inc. | Phase 1 | Completed | 94 | Aug 25, 2025 | Registry ↗ |
| Jul 22, 2025 | Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer NCT04381832 · Prostatic Neoplasms, Castration-Resistant, Androgen-Resista… Etrumadenant, Zimberelimab | RCUS Arcus Biosciences, Inc. | Phase 1/2 | Completed | 173 | Aug 30, 2024 | Registry ↗ |
| Feb 4, 2025 | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies NCT03628677 · Solid Tumor, Unspecified, Adult Domvanalimab, Zimberelimab | RCUS Arcus Biosciences, Inc. | Phase 1 | Completed | 75 | Jan 23, 2025 | Registry ↗ |
| Dec 9, 2024 | A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer NCT03846310 · Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung… Etrumadenant, Zimberelimab | RCUS Arcus Biosciences, Inc. | Phase 1 | Completed | 77 | Nov 18, 2024 | Registry ↗ |
| Oct 17, 2024 | A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers NCT05999513 · Healthy Participants casdatifan | RCUS Arcus Biosciences, Inc. | Phase 1 | Completed | 24 | Oct 31, 2023 | Registry ↗ |
| Oct 17, 2024 | Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healt… NCT05117554 · Healthy Participants casdatifan, Placebo | RCUS Arcus Biosciences, Inc. | Phase 1 | Completed | 70 | Feb 17, 2023 | Registry ↗ |
| Sep 19, 2024 | Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Adv… NCT04087018 · Advanced Solid Tumors zimberelimab | RCUS Arcus Biosciences, Inc. | Phase 1 | Completed | 18 | Jun 17, 2024 | Registry ↗ |
| Aug 28, 2024 | A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers NCT06004921 · Cancer AB801, Placebo | RCUS Arcus Biosciences, Inc. | Phase 1 | Completed | 32 | Feb 23, 2024 | Registry ↗ |
| May 24, 2024 | A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant… NCT05411146 · Healthy Participants [14C]-etrumadenant | RCUS Arcus Biosciences, Inc. | Phase 1 | Completed | 8 | Jul 7, 2022 | Registry ↗ |
| May 24, 2024 | A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Health… NCT05277012 · Healthy Participants Etrumadenant | RCUS Arcus Biosciences, Inc. | Phase 1 | Completed | 24 | Mar 31, 2022 | Registry ↗ |
| May 24, 2024 | A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile… NCT05154136 · Healthy Participants Etrumadenant, Itraconazole | RCUS Arcus Biosciences, Inc. | Phase 1 | Completed | 20 | Dec 10, 2021 | Registry ↗ |
| May 24, 2024 | A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers NCT04575311 · Healthy Volunteers AB680, Placebo | RCUS Arcus Biosciences, Inc. | Phase 1 | Completed | 32 | Sep 22, 2021 | Registry ↗ |
| May 24, 2024 | A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies NCT03720678 · GastroEsophageal Cancer, Colorectal Cancer etrumadenant, mFOLFOX | RCUS Arcus Biosciences, Inc. | Phase 1 | Completed | 44 | Jan 27, 2021 | Registry ↗ |
| May 24, 2024 | A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-N… NCT03719326 · TNBC - Triple-Negative Breast Cancer, Ovarian Cancer Etrumadenant, IPI-549 | RCUS Arcus Biosciences, Inc. | Phase 1 | Completed | 35 | Jul 1, 2021 | Registry ↗ |
| May 24, 2024 | A Study to Investigate the Safety of AB680 in Healthy Volunteers NCT03677973 · Healthy Volunteers AB680, Placebo | RCUS Arcus Biosciences, Inc. | Phase 1 | Completed | 64 | Aug 19, 2019 | Registry ↗ |
| May 24, 2024 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With… NCT03629756 · Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the… Etrumadenant, Zimberelimab | RCUS Arcus Biosciences, Inc. | Phase 1 | Completed | 48 | Aug 18, 2021 | Registry ↗ |
32 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:44 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances